Business Context and Reporting Period
Company: Fresenius Medical Care AG & Co. KGaA
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 12, 2019
Subject: Notification of a new share buy-back programme pursuant to EU Market Abuse Regulation.
Key Financial Metrics
This filing does not contain operational financial results (revenue, profit, cash flow, or margins). It details a capital allocation initiative with the following parameters:
- Buy-back Authorization: Up to 6 million ordinary shares (ISIN DE0005785802).
- Total Budget: Up to 330 million Euro (approximately 370 million U.S. Dollar), excluding ancillary transaction costs.
- Share Capital Impact: Represents approximately 1.6% of the Company's share capital.
- Execution Period: March 12, 2019, to May 10, 2019.
- Trading Venue: XETRA trading system and/or selected multilateral trading facilities (MTF).
Material Changes and Program Details
The Company is utilizing an authorization granted by the General Meeting on May 12, 2016. Key conditions include:
- Purpose: Repurchased shares will be cancelled to reduce registered share capital.
- Price Constraints: The purchase price must not deviate by more than 10% from the market price determined by the opening auction on the XETRA trading day.
- Volume Limits: Purchases are limited to no more than 25% of the average daily volume (based on the preceding 20 trading days).
- Execution: A credit institution will execute the buy-back independently of the Company to ensure compliance with safe harbour provisions.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the Company's commitment to returning capital to shareholders through share cancellation. The programme may be suspended or reinstated at any time as permitted by law.
Disclosure Obligations: Transaction details will be published on the Company's website within seven trading days of execution and retained for at least five years.
Risks: The filing does not explicitly list new risks, though the programme is subject to legal suspension and market conditions.
Investor Verification Checklist
- Verify the actual volume and average price of shares repurchased during the March 12 to May 10, 2019 window.
- Confirm the final reduction in registered share capital following the cancellation of repurchased shares.
- Review subsequent filings for any suspension or early termination of the buy-back programme.
- Check the Company's website (Investors section) for the required transaction disclosures.